Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma

Journal of Thoracic Oncology

Volumn 5, Issue 3, 2010, Pages 385-388

  Tan, Carol ^a   Barrington, Sally ^a   Rankin, Sheila ^a   Landau, David ^a   Pilling, John ^a   Spicer, James ^a   Cane, Paul ^a   Lang Lazdunski, Loïc ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Malignant mesothelioma; Multimodality therapy; PET CT; Surveillance

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; PEMETREXED;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DECORTICATION; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; DRUG UPTAKE; FEMALE; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SKULL BASE; THIGH; TREATMENT RESPONSE;

EID: 77649303314     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181cbf465     Document Type: Article

References (24)

1. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-593.
2. Mak V, Davies E, Putcha V, et al. The epidemiology and treatment of mesothelioma in South East England 1985-2002. Thorax 2008;63:160-166.
3. Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183-1185.
4. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 2005;49S1:S71-S74.
5. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457.
6. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
7. Martin-Ucar AE, Edwards JG, Rengajaran A, et al. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001;20:1117-1121.
8. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49S1:S27-S32.
9. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 2000;17:377-383.
10. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005;129:1364-1370.
11. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-1458.
12. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]Fluorodeoxyglucose. J Clin Oncol 2006;24:4587-4593.
13. Steinert HC, Santos Dellea MM, Burger C, et al. Therapy response evaluation in malignant pleural mesothelioma with intergrated PET-CT imaging. Lung Cancer 2005;49S1:S33-S35.
14. Fiore D, Baggio V, Sotti G, et al. Imaging before and after multimodal treatment for malignant pleural mesothelioma. Radiol Med 2006;111: 355-364.
15. Treasure T, Tan C, Lang-Lazdunski L, et al. The MARS trial: mesothelioma and radical surgery. Interact Cardiovasc Thorac Surg 2006;5:58-59.
16. Pagan V, Ceron L, Paccagnella A, et al. 5-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg 2006;47:595-601.
17. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-1692.
18. Jänne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin 2004;14:567-573.
19. Kernstine, KH, Grannis FW Jr, Rotter AJ. Is there a role for PET in the evaluation of subcentimeter pulmonary nodules? Semin Thorac Cardiovasc Surg 2005;17:110-114.
20. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-338.
21. Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45S1:S125-S127.
22. Powell A, Creaney J, Broomfields S, et al. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 2006;52:189-197.
23. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005;46:983-995.
24. Benard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;114:713-722.